Quantus

Samsung Biologics

A207940 · KOSPI
₩1,485,000-2.75%
2026-08-03 close

Samsung Biologics — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 295 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER 63.46 · PBR 6.3 — own history (2016-11~) percentiles 90/100 · 67/100

PER90/100
PBR67/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 3.85
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
3.85
Beneish M-Score
-2.11

No statistical flag

Sloan accrual
-3.32%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

9/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score9/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 1 of 290, share 7.3%.

1 / 2907.3%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%

Concentration

DistributedCR3 16.6%
HHI 201290 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
269

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
27.7%
Interest coverage
16.2x
Return on equity (ROE)
9.9%

Operating margin −5pp

Tolerable
Interest coverageBase 16.2x adverse case 13.3x
Return on equity (ROE)Base 9.9% adverse case 8.7%

Revenue −15%

Tolerable
Interest coverageBase 16.2x adverse case 13.8x
Return on equity (ROE)Base 9.9% adverse case 9.1%

Interest rate +2pp

Tolerable
Interest coverageBase 16.2x adverse case 6.1x
Return on equity (ROE)Base 9.9% adverse case 9.6%

Interest coverage limit

Current margin 26pp

Interest coverage limit at an operating margin of 1.7%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-05-15

Suppliers disclosed by the company in its 2026-05-15 annual report.

Suppliers without disclosed amount

아이마켓코리아Price comovement r=0.16 (1 year)CDMOResinGlobalLifeSciencesSolutionsSingaporePteLtdFilterBOM+4 more

Financials at a glance

Samsung Biologics's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 삼성물산74.32%2025-11-07 · 증감 -0.03%p

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ 3,945억 · 1w net inflow ≈ -42억(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Recent filings

Samsung Biologics's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy